CRBU · Caribou Biosciences, Inc.
Market Cap
$136.15M
Shares
107.21M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.27
Open$1.38
Day$1.26–1.40
52W close$1.27–2.84
Avg vol 30d1.1M
Short int12.5M · 11.7% float · 12.9d
Short vol59%
Last earningsMay 7, 2026
DataJul 2021–Sep 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Oct 4, 2027
Est · unconfirmed
· in 55 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$10.04M
Trailing 12 months
Net income (TTM)
−$103.40M
Trailing 12 months
Revenue growth YoY
-43.8%
Year over year
Operating margin
-1,090.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.6%
Year over year · more shares
Price change (1Y)
-33.5%
Trailing year
Short interest
11.7%
Latest settlement · 12.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−29%
below
Price vs 50-day avg
−22%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−32%
trailing
YTD return
−20%
this year
Relative strength
−50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.66% of float · ▲ +0.3% MoM · 12.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
137 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
EPS growth
+4%
Y/Y
Free cash flow
$-112.4M
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the 8-K filed Jul 16, 2024
Costs in connection with the workforce reduction, consisting pri
· third quarter of 2024
$500,000 – $1M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−29%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.66% of float · ▲ +0.3% MoM · 12.9 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
137 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $3
vs 200-day avg -29%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRBU
this stock
Caribou Biosciences, Inc.
|
$136.15M | -20.1% | +11.7% | — | 11.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRBU | -19.1% | -21.1% | -32.1% | -17.5% | -20.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -18.0% | -19.4% | -49.9% | -17.2% | -32.2% |